EURORELAX: Impact of Deep Versus Standard Muscle Relaxation on Intra-operative Safety

Sponsor
Leiden University Medical Center (Other)
Overall Status
Unknown status
CT.gov ID
NCT04124757
Collaborator
Merck Sharp & Dohme LLC (Industry)
922
8
2
24.6
115.3
4.7

Study Details

Study Description

Brief Summary

Muscle relaxants are routinely applied during anesthesia to facilitate endotracheal intubation and to improve surgical working conditions. Several investigations have shown that a deep neuromuscular block (NMB) improves the surgical working conditions over a moderate NMB and effectively precludes sudden deterioration of the surgical field. However, whether the improvement of surgical working conditions translates into less intra- and postoperative complications remains uncertain. Small prospective or retrospective studies shown an decrease of the incidence of intraoperative adverse events and postoperative complications after a deep NMB. There is a need to confirm these outcome data prospectively, in a large number of patients and clinics and during a variety of surgical procedures.

Condition or Disease Intervention/Treatment Phase
  • Other: Deep neuromuscular block
N/A

Detailed Description

Muscle relaxants are routinely applied during anesthesia to facilitate endotracheal intubation and to improve surgical working conditions. Several investigations have shown that a deep neuromuscular block (NMB) (post tetanic count (PTC) 1-2 twitches) improves the surgical working conditions over a moderate NMB (TOF count 1-3 twitches) and effectively precludes sudden deterioration of the surgical field. However, whether the improvement of surgical working conditions translates into less intra- and postoperative complications remains uncertain. A recent retrospective analysis of neuromuscular management during laparoscopic retroperitoneal surgery showed a reduced rate of unplanned 30 day readmissions when a deep NMB over a moderate NMB was applied (3.8% vs. 12.7%).In addition, a pooled analysis of 4 randomized controlled trials comparing different levels of intra-abdominal pressure and neuromuscular blockade during laparoscopic donor nephrectomy, showed a significant reduction in the incidence of intra-operative surgical complications from 12.6% with moderate NMB to 4.8% with deep NMB.

These previous observations were made in small prospective or retrospective studies. There is a need to confirm these outcome data prospectively, in a larger prospective trial for a variety of surgical procedures. We therefore propose a multi-center, randomized controlled trial, to study the effect of a deep NMB (PTC 1-2 twitches) versus standard NMB (single induction dose rocuronium) in a variety of laparoscopic surgical procedures on the incidence of intraoperative adverse events and postoperative outcome data.

In this study the effect of deep neuromuscular block compared to standard neuromuscular block on intra-operative adverse events during laparoscopic surgery using the CLASSIC score system is evaluated.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
922 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
The Impact of Deep Versus Standard Muscle Relaxation on Intra-operative Safety During Laparoscopic Surgery: a Multicenter Strategy Study
Actual Study Start Date :
Feb 11, 2020
Anticipated Primary Completion Date :
Sep 1, 2021
Anticipated Study Completion Date :
Mar 1, 2022

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Standard neuromuscular blockade

Subjects will receive regular rocuronium induction dose, followed by bolus foses of 10 mg in case of insufficient conditions

Experimental: Deep neuromuscular block

Subjects will receive high dose rocuronium induction dose followed by continuous rocuronium administration, to achieve a depth of neuromuscular block of 1-2 twitches post tetanic count

Other: Deep neuromuscular block
Deep neuromuscular block will be achieved with high dose rocuronium to achieve a depth of 1-2 twitches post tetanic count
Other Names:
  • High dose rocuronium
  • Outcome Measures

    Primary Outcome Measures

    1. Classic score [Day of surgery]

      To study the effect of deep neuromuscular block compared to standard neuromuscular block on intra-operative adverse events during laparoscopic surgery using the CLASSIC score system. (The Classic score; classification of intraoperative complications, is a 6 point scale ranging from no complications (0) to fatal complications (5).

    Secondary Outcome Measures

    1. L-SRS (Leiden Surgical Rating Scale) [Day of surgery]

      To study the effect of deep neuromuscular block compared to standard neuromuscular block on peroperative surgical working conditions following the Leiden Surgical Rating scale (a 5 point scale, ranging from poor (1) to excellent (5) surgical conditions.

    2. 30 day post-operative complications [30 postoperative days]

      To study the effect of deep neuromuscular block compared to standard neuromuscular block on 30 day post-operative complications according the Clavien-Dindo score en Comprehensive Complication Index and unplanned readmissions

    3. Quality of recovery (QoR) [2 postoperative days]

      To study the effect of deep neuromuscular block compared to standard neuromuscular block on Quality of Recovery at post-operative day 1, 2 according to the Quality of Recovery-40

    4. Quality of life (QoL) [30 postoperative days]

      To study the effect of deep neuromuscular block compared to standard neuromuscular block on Quality of life at post-operative day 30 Short Form-36

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients scheduled for elective laparoscopic procedure with a complexity according to the BUPA classification for case complexity: 'MAJOR', 'MAJOR Plus or 'COMPLEX MAJOR'

    • ASA (merican society of anesthesiologists) class I-III

    • 18 years of age

    • Ability to give oral and written informed consent

    Exclusion Criteria:
    • Low or intermediate complexity laparoscopic procedures (BUPA 'SIMPLE' or 'INTER')

    • Known or suspected neuromuscular disorders impairing neuromuscular function

    • Allergies to muscle relaxants, anesthetics or narcotics mentioned in paragraph 5.2

    • A (family) history of malignant hyperthermia

    • Women who are or may be pregnant or are currently breast feeding

    • Chronic use of any type of opioid or psychotropic drug

    • Use of NSAID's shorter than 5 days before surgery

    • Indication for rapid sequence induction

    • Contra-indication for sugammadex use (e.g. known sugammadex allergy or Glomerular Filtration Rate <30 ml/min)

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Université De Lorraine Nancy Meurthe-et-Moselle France 54000
    2 Istituto Nazionale Dei Tumori Milano Italy 20133
    3 RadboudUMC Nijmegen Gelderland Netherlands 6525GA
    4 LUMC Leiden Zuid-Holland Netherlands 2333ZA
    5 Noordwest ziekenhuis groep Alkmaar Netherlands 1815 JD
    6 Netherlands Cancer institute Amsterdam Netherlands 1066 CX
    7 Canisius Wilhelmina Ziekenhuis Nijmegen Netherlands 6532 SZ
    8 Hospital Universitari I Politecnic La Fe Valencia Spain 46026

    Sponsors and Collaborators

    • Leiden University Medical Center
    • Merck Sharp & Dohme LLC

    Investigators

    • Principal Investigator: Monique van Velzen, PhD, LUMC

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    Martijn Boon, Prinicipal Investigator, Leiden University Medical Center
    ClinicalTrials.gov Identifier:
    NCT04124757
    Other Study ID Numbers:
    • P19.065
    First Posted:
    Oct 11, 2019
    Last Update Posted:
    Feb 17, 2020
    Last Verified:
    Feb 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Martijn Boon, Prinicipal Investigator, Leiden University Medical Center
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 17, 2020